Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Legal Officer | January 16, 2018 | January 18, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date January 16, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 25,204 |
Ending reported balance
After 2018-01-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-01-16 · Sale · Disposed 45,000 · Balance 25,204 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Row 2 · 2018-01-16 · Exercise / conversion · Acquired 1,110 · Balance 26,314 Row 3 · 2018-01-16 · Sale · Disposed 1,110 · Balance 25,204 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Row 4 · 2018-01-16 · Exercise / conversion · Acquired 19,890 · Balance 45,094 Row 5 · 2018-01-16 · Sale · Disposed 19,890 · Balance 25,204 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2026-07-15 | Direct | 36,663 |
Reported balance
After 2018-01-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-01-16 · Exercise / conversion · Disposed 1,110 · Balance 36,663 F4: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2026-07-15 | Direct | 5,237 |
Reported balance
After 2018-01-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-01-16 · Exercise / conversion · Disposed 19,890 · Balance 5,237 F5: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
F5: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,890 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · derivative · entry 7 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237 Underlying: Common Shares · 19,890 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,110 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · derivative · entry 6 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,663 Underlying: Common Shares · 1,110 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 19,890 | $28.10 | $558,909.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 19,890 | $12.57 | $250,017.30 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,110 | $28.24 | $31,346.40 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 1,110 | $12.57 | $13,952.70 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 45,000 | $28.00 | $1,260,000.00 |
DisclosureSEC source: 0000899243-18-001348 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,510 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · derivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,157 Underlying: Common Shares · 1,510 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,490 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · derivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,773 Underlying: Common Shares · 6,490 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,000 | $25.75 | $206,000.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 8,000 | $12.57 | $100,560.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 00:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 30,000 | $20.55 | $616,500.00 |
DisclosureSEC source: 0000899243-18-000520 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.5788 to $25.71, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,070 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 11 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,263 Underlying: Common Shares · 9,070 shares Expires 2026-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,230 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 10 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,070 Underlying: Common Shares · 6,230 shares Expires 2027-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,000 | $22.68 | $340,200.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 8 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,000 | $23.76 | $190,080.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 7 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,070 | $21.75 | $23,272.50 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 6 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 9,070 | $12.57 | $114,009.90 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 5 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,230 | $21.75 | $135,502.50 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 4 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,230 | $14.43 | $89,898.90 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · derivative · entry 9 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,300 Underlying: Common Shares · 700 shares Expires 2027-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 700 | $21.75 | $15,225.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:18 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 700 | $14.43 | $10,101.00 |
DisclosureSEC source: 0000899243-18-000074 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2017 Filed Dec 27, 2017 21:17 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,000 | $20.55 | $308,250.00 |
DisclosureSEC source: 0000899243-17-029619 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.5504 to $20.56, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:10 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,000 | $18.90 | $283,495.50 |
DisclosureSEC source: 0000899243-17-029163 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.70 to $19.32, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 08, 2017 Filed Aug 8, 2017 21:52 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,313 | $18.60 | $24,421.54 |
DisclosureSEC source: 0000899243-17-019847 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $18.82, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 21:52 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 13,210 | $18.56 | $245,209.30 |
DisclosureSEC source: 0000899243-17-019847 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,517 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.55 to $18.92, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 21:52 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 477 | $18.55 | $8,848.35 |
DisclosureSEC source: 0000899243-17-019847 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,727 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-17-016675 · doc4.xml · derivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:17 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,852 | $16.61 | $30,753.39 |
DisclosureSEC source: 0000899243-17-011672 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.55 to $16.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 22:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,912 | $16.62 | $81,637.93 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,056 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.55 to $16.86, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 13,527 | $16.84 | $227,798.74 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $17.02, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,200 | $16.76 | $53,640.64 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,800 | $16.87 | $80,989.92 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,695 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,522 | $16.44 | $57,897.10 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.91, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,010 | $17.02 | $51,222.37 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,017 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 to $17.21, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:31 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,937 | $17.37 | $51,025.09 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.11 to $17.59, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:31 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,310 | $18.58 | $42,915.64 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,964 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.12 to $18.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:31 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,930 | $17.49 | $86,249.36 |
DisclosureSEC source: 0000899243-17-010730 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,274 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $17.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.